Oncology Hematology Care

 

OHC-390x227

Molly Mendenhall, RN, BSN, Director of Quality and Compliance
Oncology Hematology Care, Inc. (OHC)
Cincinnati, Ohio

Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing in NSCLC

A one-year quality improvement (QI) project implemented and standardized comprehensive biomarker testing in patients with metastatic non-small cell lung cancer (NSCLC). Custom data reports and monitoring dashboards ensured practice-wide adoption and sustainability across multiple clinic sites. After increasing biomarker testing rates from 68% to 92.7%, this QI project is now being scaled across the country through the US Oncology Network, McKesson as a best-practice initiative.

 

Watch Video

Read Blog

Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing in NSCLC

2023-innovator-awards-200x200In a constantly evolving oncology landscape, streamlining care delivery models has become a significant challenge for cancer programs and practices around the United States. Understanding this, Oncology Hematology Care, Inc. (OHC), has spent the last few years developing initiatives aimed at ensuring their patients continue to receive next-generation cancer care. Among their more recent endeavors was a one-year quality improvement project designed to implement and standardize comprehensive biomarker testing in patients with metastatic non-small cell lung cancer (NSCLC).
Read Full Story

 
 

Featured in Oncology Issues

V39-N1-A-Model-for-Achieving-Comprehensive-Biomarker-Testing-in-Non–Small-Cell-Lung-Cancer-220x285A Model for Achieving Comprehensive Biomarker Testing in Non–Small Cell Lung Cancer

Nearly 70% of the positive biomarkers will have an impact on a patient’s first line treatment selection.
Read Full Story